

The White House Commission on Complementary and Alternative Medicine was established to provide legislative and administrative recommendations for ensuring that public policy maximizes the potential benefits of Complementary and Alternative Medicine (CAM) therapies to consumers. The Commission was asked to provide a report to the President, through the Secretary, Department of Health and Human Services and address the following issues (1) the education and training of health care practitioners in CAM; (2) coordination of research to increase knowledge about CAM practices and products; (3) the provision to health care professionals of reliable and useful information about CAM that can be made readily accessible and understandable to the general public; and (4) guidance for the appropriate access to and delivery of complementary and alternative medicine.

The Commission considered the needs, concerns, and experiences of patients, their families, health care practitioners, research investigators, ^{representatives of health insurers and} manufacturers and suppliers of ^{managed} CAM products, voluntary organizations, private foundations and the Federal agencies ^{care organizations,} associated with CAM activities. In the report the Commission presents the ^{benefit experts} Administration and Congress with recommendations and implementation actions to guide the nation's policies regarding CAM into the new century. It has been an honor to listen to the oral testimony and receive written testimony from supporters and critics alike on

*Earl Stansbury
Charles
Cavallo* *Access
Administration etc*

the issues before the Commission. It is a privilege to present these identified need^s and suggested actions to the President, the Secretary of ^{the Department of Health and Human Services} DHHS and the Congress, and the public. The Commission looks forward to the implementation of the recommendations and actions in this report.

Many individuals and organizations assisted the Commission. The Commission is most grateful to the hundreds of individuals who devoted personal time ^{and traveled great distances} to participate in the ten general meetings of the Commission and the four Town Hall meetings held in San Francisco, CA, Seattle, WA, New York City, NY and Minneapolis, MN. Their enthusiasm and willingness to assist the Commission deserve special thanks. The Commission also thanks the many people who traveled from great distant to participate in the open Public Session, even with restricted time available for their presentations.

The Commission gratefully acknowledges the efforts and contributions of the Commission's staff including Ms. Michele Chang, Executive Secretary to the Commission, Commander Corinne Axelrod, Dr. Kenneth Fisher, Captain Joseph Kaczmarczyk, Ms. Maureen Miller, Dr. Max Heirich, Ms. Geraldine Pollen, Mr. James Swyers and Ms. Joan Albrecht.

Considerable effort was required to develop agenda issues and fully explore appropriate speakers and background information on issues prior to the discussion at the meeting^s on issue prior to the discussion at the public meetings.

Jim

Several individuals assisted the Commission in important consultant roles. The conscientious efforts of Dr. Ken Fisher, Ms. Maureen Miller, Mr. Jim Swyers and Dr. Max Heirich are particularly recognized.

A special mention of thanks is extended to Ms. Jean Kazares and Ms. Anita Allen of Palladian Partners who provided logistical support services to the Commission. A special thank you is given to the copy editor, ^{Ms. Burns} Blair Potter ~~BURNS~~ for her talents and assistance in editing the final report of the Commission.

Stephen C. Groft, Pharm.D.
Executive Director
White House Commission on Complementary
and Alternative Medicine Policy

Christine Taylor, Ph.D., Director, Office of Special
Nutritionals, Center for Food Safety and Nutrition, FDA
for her assistance and guidance during the review
of dietary supplements
Christine Louise Taylor, Ph.D.

Many individuals in the Federal sector assisted the Commission
from whom we are unable to mention all who participated assisted,
but there are many persons who deserve a special thanks:

Mr. Stephen Straus, Director, National Center for
Complementary and Alternative Medicine ~~for~~ for
providing administrative support and facilitating the Commission's activities
Mr. William Harlan, Acting Director, National Center for
Complementary and Alternative Medicine for his
support and attention at the time of the formation of the
Commission

Mr. Paul Carter, Director, Office of Dietary Supplements
at the National Institutes of Health for his thoughtful
comments and ~~consideration~~ consideration of the various
issues before the Commission

Add to Acknowledgment

WHITE HOUSE COMMISSION ON COMPLEMENTARY AND ALTERNATIVE MEDICINE POLICY
Alan Dumoff, J.D., M.S.W.

The following concerns are based upon twelve years of experience representing holistic physicians and complementary and alternative health care practitioners. The issues raised here affect many of my clients and most are generally recognized within the field as legal barriers to integrative practice.

ACKNOWLEDGEMENTS

The National Commission on Orphan Diseases was established to assess the activities of the private and public sector in connection with the various aspects of rare diseases. These include basic and clinical research, the need for and dissemination of information to the public and health professionals, availability of health insurance and reimbursement for patients with rare diseases, as well as the discovery and development of orphan products for rare diseases. The National Commission on Orphan Diseases considered the needs of patients, physicians, researchers, the pharmaceutical industry, voluntary organizations, private foundations and the Federal agencies associated with all rare diseases. In this report, the Commission presents Congress and the Administration a blueprint to guide the country's policies regarding rare diseases into the 21st Century. It is a privilege to present the needs of these patients to the public. The Commission looks forward to the implementation of the recommendations in this report.

Many individuals and organizations assisted the Commission. We are unable to mention all who assisted, but there are many persons who deserve a special thanks:

Dr. Robert E. Windom, Assistant Secretary for Health, Department of Health and Human Services, for his support and attention at the time of the formation of the Commission and during its deliberations;

Mr. Wilford Forbush, Deputy Assistant Secretary for Health Operations, for providing administrative support and facilitating the Commission's activities;

Dr. Jay Moskowitz, Associate Director for Science Policy and Legislation, and Dr. Jerome Green, Director, Division of Research Grants at the National Institutes of Health, for their assistance in retrieving and reviewing information and data from the Bureaus, Institutes, and Divisions of NIH.

A special thank you is given to the principal editor, Blair Burns Potter who wove the results of the surveys, written and oral testimony, and recommendations of the Commission into this final report. Also a note of thanks to Dr. Tom Truss who shared his writing and editing talents with the Commission.

Several individuals assisted the Commission in the design and analysis of the numerous surveys conducted by the Commission. The conscientious efforts of Dr. Louis A. Morris, Dr. Arthur Kirsch and Dr. John L. Swasy are particularly recognized. The Commission also appreciates the cooperation of the many patients, physicians, investiga-

tors and representatives of government agencies, voluntary rare disease organizations, foundations, and pharmaceutical manufacturers who provided essential information for the surveys and discussions conducted by the Commission.

Several organizations conducted or sponsored surveys and transmitted the results to the Commission. Their enthusiasm and willingness to assist the Commission's data gathering efforts deserves special thanks. These organizations and their representatives follow:

American Medical Association—Dr. Lorayn Olson and Dr. Paul D. Frenzen

Chilton Research Services—Dr. David B. Lambert, Gwen Miller, and Lorie McCafferty

Hamilton, Fredericks, and Schneider—Pat Junkins and James Gill

Macro Systems, Inc.—Dr. Jean Cohen

The National Organization for Rare Diseases—Abbey Meyers

The Rockefeller University—Dr. D. Martin Carter

The Pharmaceutical Manufacturers Association—Dr. Lawrence Weaver, Dr. George Goldstein, and Gerald J. Mossinghoff

The Generic Pharmaceutical Industry—Dee Fensterer

The Orphan Developers Coalition—John Presutti

The Association of Biotechnology Companies—Jeffrey N. Gibbs

The Commission gratefully acknowledges the efforts and contributions of the Commission's staff including Dr. Mary Custer, Henrietta Hyatt-Knorr, Beatrice Anderson, and Carol Lewis. A special mention of thanks to Paris Pacchione, Donna Young, Frank Teets, and the Electronic Phototypesetting Section (Printing Management) for assistance in preparing the report for publication. In addition, the computer support staff provided by Management Systems Applications, Inc., in particular, Frank Newman and Bill Kibby, minimized down time and kept the computer system working through many deadlines.

Stephen C. Groft, Pharm.D.
Executive Director

Chapter 16 bold no underline
skip space
text

1st subheading 14 bold no underline
skip space

2nd subheading 12^{bold} underline
text (do not skip)

skip space
next subheading 12 bold underline
text